Novartis Halts Development Of Antibiotic Booster Acquired In NeuTec Deal
This article was originally published in The Pink Sheet Daily
Drug maker will take a $235 million charge in the third quarter as a result.
You may also be interested in...
Proposed acquisition of NeuTec would give Novartis two Phase III therapies for its nosocomial arsenal.
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.